ScreenerHero

CVMCEL-SCI Corporation

AMEX · US · Healthcare · Biotechnology · cel-sci.com
1.420USD-13.41%Mkt Cap: 24.98M $P/E: —

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap24.98M $
Enterprise Value26.34M $
Revenue (TTM)—
Gross Profit-15.89M $
Net Income (TTM)-25.41M $
Revenue/Share—
Last Price1.420 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.22
PEG1.12
EV/EBITDA-1.30
EV/Revenue—
P/S—
P/B2.28
EPS (TTM)-1.69
EPS (Forward)-6.38
52W Range
0.89004% of range13.48
52W High13.48 USD
52W Low0.8900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-159.25%
ROA-90.25%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.12M $
CapEx (TTM)38.11K $
FCF Margin—
FCF Yield-34.00%
Net Debt1.36M $
Net Debt/EBITDA-0.07
Balance Sheet
Debt/Equity0.59
Current Ratio1.48
Quick Ratio1.29
Book Value/Sh0.6230 USD
Cash/Share0.3720 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateAug 28, 1996
Pay DateJun 15, 2017
Splits
Last Split1:30
Split DateMay 20, 2025
Analyst Consensus
Rating—
Target (Mean)12.50 USD
Upside (mean)+780.3%
Target Range10.00 USD – 15.00 USD
$10.00+780.3% to mean$15.00
# Analysts2
Ownership
Shares Out.17.59M
Float17.02M
Insiders6.27%
Institutions11.52%
Short Interest
Short Ratio3.4d
Short % Float7.09%
Short % Out.6.87%
Shares Short1.20M
Short (prev mo.)263.54K
Technical
SMA 501.259 (+12.8%)
SMA 2003.594 (-60.5%)
Beta—
S&P 52W Chg19.18%
Avg Vol (30d)275.91K
Avg Vol (10d)165.00K
Technical Indicators
RSI (14)50.8
MACD0.0772
MACD Signal0.0690
MACD Hist.+0.0082
BB Upper1.766 USD
BB Middle1.393 USD
BB Lower1.020 USD
BB Width53.50%
ATR (14)0.1331 USD
Vol Ratio (20d)0.32x